NCT02094573View on ClinicalTrials.gov

A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

PHASE2CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

June 4, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 27, 2020

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Brigatinib

Brigatinib tablets

Sponsors
All Listed Sponsors
lead

Ariad Pharmaceuticals

INDUSTRY

NCT02094573 - A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | Biotech Hunter | Biotech Hunter